相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Outbreak of ceftazidime-avibactam resistant Klebsiella pneumoniae carbapenemase pneumoniae in a COVID-19 intensive care unit, Italy: urgent need for updated diagnostic protocols of surveillance cultures
G. Bianco et al.
JOURNAL OF HOSPITAL INFECTION (2022)
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Christopher J. L. Murray et al.
LANCET (2022)
Resistome and virulome accretion in an NDM-1-producing ST147 sublineage of Klebsiella pneumoniae associated with an outbreak in Tuscany, Italy: a genotypic and phenotypic characterisation
Vincenzo Di Pilato et al.
LANCET MICROBE (2022)
Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate
Paolo Gaibani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies
Ilias Karaiskos et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing
Paolo Gaibani et al.
ANTIBIOTICS-BASEL (2022)
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam
J. Nicholas O'Donnell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Widespread emergence of OmpK36 loop 3 insertions among multidrug-resistant clones of Klebsiella pneumoniae
Sophia David et al.
PLOS PATHOGENS (2022)
KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam
Vincenzo Di Pilato et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Anatomy of an extensively drug-resistant Klebsiella pneumoniae outbreak in Tuscany, Italy
Melissa J. Martin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect
Claire Amaris Hobson et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations
Irene Galani et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates
Alessandra Carattoli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies
Stefano Di Bella et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Ceftazidime-Avibactam Resistance Associated with Increased blaKPC-3 Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 Klebsiella pneumoniae
Marco Coppi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
Irene Galani et al.
EUROSURVEILLANCE (2020)
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
Andrea Novelli et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Phenotypic, Biochemical, and Genetic Analysis of KPC-41, a KPC-3 Variant Conferring Resistance to Ceftazidime-Avibactam and Exhibiting Reduced Carbapenemase Activity
Linda Mueller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections
Krisztina M. Papp-Wallace
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
Alessandro Cassini et al.
LANCET INFECTIOUS DISEASES (2019)
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae
Dongxu Sun et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Resistance to Ceftazidime-Avibactam in Klebsiella pneumoniae Due to Porin Mutations and the Increased Expression of KPC-3
Romney M. Humphries et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Characterization of KPC-encoding plasmids from two endemic settings, Greece and Italy
Costas C. Papagiannitsis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions
L. S. Tzouvelekis et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Functional Characterization of Tn4401, a Tn3-Based Transposon Involved in blaKPC Gene Mobilization
Gaelle Cuzon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)